(NASDAQ: ARVN) Arvinas's forecast annual revenue growth rate of -19.99% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.43%.
Arvinas's revenue in 2026 is $312,300,000.On average, 19 Wall Street analysts forecast ARVN's revenue for 2026 to be $5,973,694,258, with the lowest ARVN revenue forecast at $1,044,800,815, and the highest ARVN revenue forecast at $11,585,420,395. On average, 15 Wall Street analysts forecast ARVN's revenue for 2027 to be $6,008,824,947, with the lowest ARVN revenue forecast at $2,061,920,959, and the highest ARVN revenue forecast at $13,265,527,926.
In 2028, ARVN is forecast to generate $11,747,265,616 in revenue, with the lowest revenue forecast at $2,265,833,092 and the highest revenue forecast at $37,082,465,113.